皮佩拉西林/塔佐巴克坦诱导的免疫媒介性贫血和血小板缺血
Agnes-Sophie Fritz1, Marten Trendelenburg1, Markus Mutke1
1Department of Internal Medicine, University Hospital of Basel, Basel, Switzerland.
European journal of case reports in internal medicine
|September 10, 2025
概括
皮佩拉西林/塔扎巴克坦可以引起免疫媒介的双细胞减退,包括溶血性贫血和血栓减退. 免疫系统改变的患者可能面临这种抗生素组合的风险增加.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮佩拉西林/塔扎巴克坦 (PTZ) 已被认为会导致细胞衰减.
- 病例报告详细介绍PTZ诱导的联合血液溶解性贫血和血小板缺血是罕见的.
研究的目的:
- 报告与piperacillin/tazobactam相关的严重的免疫媒介双细胞衰减病例 (血液溶解性贫血和血小板衰竭).
- 为了突出piperacillin/tazobactam诱导联合血液学异常的潜力.
主要方法:
- 一个56岁的男性患者的病例报告.
- 在两次单独的PTZ治疗期间观察血液学参数.
- 评估患者对PTZ停止和重新挑战的反应.
主要成果:
- 患者在两次PTZ治疗过程中出现了严重的免疫媒介性血小板缩和贫血.
- 在第一个PTZ停药后,血清正常化,但在重新挑战时再次下降.
- 第二次PTZ暴露后的恢复延迟了,这表明持续的影响.
结论:
- 皮佩拉西林/塔扎巴克坦可以诱导免疫媒介的血液溶解性贫血和血小板狭窄症.
- 具有先前存在的免疫系统改变的个体可能有更高的风险发展PTZ诱导的双细胞衰退.
相关概念视频
Pulmonary Tuberculosis I
846
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
846
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233
Acute Pyelonephritis II: Diagnostic Studies and Management
323
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
323
Desensitization and Tachyphylaxis
3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271
Pneumonia IV: Management
764
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
764


